Novavax to Present at the 13th Annual Needham Healthcare Conference
April 02 2014 - 4:11PM
GAITHERSBURG, Md., April 2, 2014 (GLOBE NEWSWIRE)
-- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company,
announced today that Stanley C. Erck, President and Chief Executive
Officer, will present at the 13th Annual Needham Healthcare
Conference on April 9, 2014 at 12:10 pm ET in New York City at the
Westin Grand Central Hotel.
A live webcast link for the presentation will be
available via the company website at www.novavax.com under Investor
Info/Events.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biopharmaceutical company creating novel vaccines and vaccine
adjuvants to address a broad range of infectious diseases
worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine
candidates to efficiently and effectively respond to both known and
newly emergent diseases. Novavax is involved in several
international partnerships, including collaborations with Cadila
Pharmaceuticals of India, LG Life Sciences of Korea and PATH, and
recently acquired Isconova AB, a leading vaccine adjuvant company
located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information
about Novavax is available on the company's website,
novavax.com.
Forward-Looking
Statements
Statements herein relating to
the future of Novavax and the ongoing development of its vaccine
and adjuvant products are forward-looking statements. Novavax
cautions that these forward looking statements are subject to
numerous risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include those identified
under the heading "Risk Factors" in the Novavax Annual Report on
Form 10-K for the year ended December 31, 2013, filed with the
Securities and Exchange Commission (SEC). Investors are cautioned
not to place considerable reliance on the forward-looking
statements contained in this press release. You are encouraged to
read company filings with the SEC, available at sec.gov, for a
discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this document, and the company undertakes no obligation
to update or revise any of the statements. The company's business
is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should
give careful consideration to these risks and
uncertainties.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1773992
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024